Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thy
Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on
| Condition(s) | Medullary Thyroid Carcinoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC. |
| Who can participate | Inclusion Criteria: * Patients of either gender, aged ≥ 18 years and ≤80 years. * Patients with pathologic findings confirming the diagnosis of MTC * Patients with MTC recurrence * Signed written consent Exclusion Criteria: * Pregnant or breastfeeding female patients * Patients with claustrophobic behavior * The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | First Affiliated Hospital of Fujian Medical University |
| Locations | Fuzhou, Fujian, China |
| Start date | 2023-06-21 |
| NCT ID | NCT06520319 |
| Official listing | https://clinicaltrials.gov/study/NCT06520319 |